Literature DB >> 15088777

Haemagglutination-inhibiting antibody to influenza virus.

J C de Jong1, A M Palache, W E P Beyer, G F Rimmelzwaan, A C M Boon, A D M E Osterhaus.   

Abstract

The results of the haemagglutination-inhibiting (HI) antibody test for influenza virus antibody in human sera closely match those produced by virus neutralization assays and are predictive of protection. On the basis of the data derived from 12 publications concerning healthy adults, we estimated the median HI titre protecting 50% of the vaccinees against the virus concerned at 28. This finding supports the current policy requiring vaccines to induce serum HI titres of > or = 40 to the vaccine viruses in the majority of the vaccinees. Unfortunately similar studies are scanty for the elderly, the group most at risk of influenza. There still remain many unsolved technical problems with the HI assay and we recommend that these problems be studied and the virus neutralization test as a predictor of resistance to influenza be assessed. Although the studies on this issue often give conflicting results, they generally show that HI antibody responses to influenza vaccination tend to diminish with increasing age, when health is often compromized. Advanced age in itself seems not to be an independent factor in this process. However, even in completely healthy elderly individuals the response to vaccination with an antigenically new virus may be strongly reduced compared with younger vaccinees.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15088777

Source DB:  PubMed          Journal:  Dev Biol (Basel)        ISSN: 1424-6074


  140 in total

Review 1.  Inactivated influenza vaccines: recent progress and implications for the elderly.

Authors:  Valentina Parodi; Daniela de Florentiis; Mariano Martini; Filippo Ansaldi
Journal:  Drugs Aging       Date:  2011-02-01       Impact factor: 3.923

2.  Estimated cumulative incidence of pandemic (H1N1) influenza among pregnant women during the first wave of the 2009 pandemic.

Authors:  Salaheddin M Mahmud; Marissa Becker; Yoav Keynan; Lawrence Elliott; Laura H Thompson; Keith Fowke; Lisa Avery; Paul Van Caeseele; Sande Harlos; James Blanchard; Magdy Dawood
Journal:  CMAJ       Date:  2010-09-07       Impact factor: 8.262

3.  A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes.

Authors:  Laurent Coudeville; Philippe Andre; Fabrice Bailleux; Françoise Weber; Stanley Plotkin
Journal:  Hum Vaccin       Date:  2010-10-01

4.  Cross-reactive neutralizing antibody against pandemic 2009 H1N1 influenza a virus in intravenous immunoglobulin preparations.

Authors:  David K Hong; Adriana H Tremoulet; Jane C Burns; David B Lewis
Journal:  Pediatr Infect Dis J       Date:  2011-01       Impact factor: 2.129

5.  Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories.

Authors:  Mary Zacour; Brian J Ward; Angela Brewer; Patrick Tang; Guy Boivin; Yan Li; Michelle Warhuus; Shelly A McNeil; Jason J LeBlanc; Todd F Hatchette
Journal:  Clin Vaccine Immunol       Date:  2016-01-27

6.  Response to influenza vaccine in people with non-protective HI antibody titers.

Authors:  Vincenzo Baldo; Tatjana Baldovin; Annarosa Floreani; Michele Minuzzo; Renzo Trivello
Journal:  Eur J Epidemiol       Date:  2006-11-03       Impact factor: 8.082

7.  Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens.

Authors:  Davide Bedognetti; Gabriele Zoppoli; Carlotta Massucco; Elisa Zanardi; Simonetta Zupo; Andrea Bruzzone; Mario Roberto Sertoli; Enrico Balleari; Omar Racchi; Marco Messina; Graziano Caltabiano; Giancarlo Icardi; Paolo Durando; Francesco M Marincola; Francesco Boccardo; Manlio Ferrarini; Filippo Ansaldi; Andrea De Maria
Journal:  J Immunol       Date:  2011-04-15       Impact factor: 5.422

Review 8.  Vaccination of patients with autoimmune inflammatory rheumatic diseases.

Authors:  Johanna Westra; Christien Rondaan; Sander van Assen; Marc Bijl
Journal:  Nat Rev Rheumatol       Date:  2014-12-09       Impact factor: 20.543

9.  Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge.

Authors:  Zhiyuan Wen; Ling Ye; Yulong Gao; Lei Pan; Ke Dong; Zhigao Bu; Richard W Compans; Chinglai Yang
Journal:  Antiviral Res       Date:  2009-09-20       Impact factor: 5.970

10.  Influenza virus inactivation for studies of antigenicity and phenotypic neuraminidase inhibitor resistance profiling.

Authors:  Marcel Jonges; Wai Ming Liu; Erhard van der Vries; Ronald Jacobi; Inge Pronk; Claire Boog; Marion Koopmans; Adam Meijer; Ernst Soethout
Journal:  J Clin Microbiol       Date:  2010-01-20       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.